Veeva Systems is expected to report consensus revenue of $905.3 million and a non-GAAP EPS of $2.22, with the stock currently trading near $248.06 against an average analyst price target of $258.08.
Investors are primarily focused on the growth trajectory of subscription revenue as the company navigates the large-scale migration of customers from Salesforce to its proprietary Vault CRM platform.
Recent momentum is supported by high-profile wins, including Eli Lilly’s global commitment to the Vault CRM Suite and the rollout of the 'Falcon' AI platform designed to automate clinical and commercial workflows.
Analysts at Stifel and TD Cowen anticipate a potential beat in subscription billings, looking for signs that stabilizing life sciences R&D spending will allow management to raise full-year fiscal 2027 guidance.